Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 1

A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)

NCT07300267 · View on ClinicalTrials.gov ↗

Study Summary

Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae. V118C is a new vaccine designed to help prevent disease from Streptococcus pneumoniae bacteria. This study will look at V118C in toddlers and infants. The goal of the study is to learn how safe V118C is for children and how well they tolerate it.

Conditions Studied

Interventions

  • BIOLOGICAL V118C (Stage 1)
  • BIOLOGICAL V118C (Stage 2)
  • BIOLOGICAL PCV20 (Stage 1)
  • BIOLOGICAL PCV20 (Stage 2)

Study Locations (12)

Texas

  • Epic Medical Research - Carrollton ( Site 1038) — Carrollton
  • Epic Medical Research- Garland ( Site 1017) — Garland
  • University of Texas Medical Branch ( Site 1020) — League City

South Carolina

  • Tribe Clinical Research, LLC-Pediatrics ( Site 1008) — Greenville
  • Tribe Clinical Research - Spartanburg ( Site 1001) — Spartanburg

California

  • Madera Family Medical Group ( Site 1004) — Madera

Florida

  • Acevedo Clinical Research Associates ( Site 1029) — Miami

Kansas

  • Cotton O'Neil Research Center ( Site 1039) — Topeka

Kentucky

  • University of Louisville, Norton Children's Research Institute ( Site 1005) — Louisville

Missouri

  • Saint Louis University Center for Vaccine Development ( Site 1031) — St Louis

New York

  • Child Health Care Associates ( Site 1035) — East Syracuse

Trial Details

FieldValue
Enrollment Target 210 participants
Start Date 2026-01-13
Est. Completion 2029-05-25
Phase Phase 1

Sponsor

Merck Sharp & Dohme

741 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07300267

The ClinicalTrials.gov registry entry for NCT07300267 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 741 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Pneumococcal Infection appearing as the primary indexed condition, and to 4 interventions — of which V118C (Stage 1) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07300267 reports 12 study locations spanning 9 distinct geographic areas — top geographies include Texas, South Carolina, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07300267 about?

NCT07300267 is a clinical study titled "A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)". Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae. V118C is a new vaccine designed to help prevent disease from Streptococcus pneumoniae bacteri...

What is the current status of trial NCT07300267?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 210 participants. The study started on 2026-01-13. Estimated completion is 2029-05-25.

What conditions does trial NCT07300267 study?

This clinical trial studies the following conditions: Pneumococcal Infection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07300267?

The interventions under investigation include: V118C (Stage 1) (BIOLOGICAL), V118C (Stage 2) (BIOLOGICAL), PCV20 (Stage 1) (BIOLOGICAL), PCV20 (Stage 2) (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07300267?

This trial is sponsored by Merck Sharp & Dohme, which has 741 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07300267 being conducted?

This trial has 12 study locations across California, Florida, Kansas, Kentucky, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial